MOLT-4
Zellname |
Beschreibung |
Bestell-Nr. |
Einheit |
Preis, Euro |
|---|---|---|---|---|
MOLT-4 |
Humane T-Zell Leukämie Zell-Linie |
300115 |
cryovial |
265,00 |
MOLT-4 |
Humane T-Zell Leukämie Zell-Linie |
330115 |
vital |
335,00 |
| Designation: | MOLT-4 |
| Depositor: | Nowada |
| Organism: | Homo sapiens (human) |
| Age/Stage: | 19 years |
| Gender: | male |
| Tissue: | Blood |
| Morphology: | lymphoblast |
| Celltype: | T lymphoblast (ALL, acute lymphoblastic leukemia) |
| Growth Properties: | suspension |
| Description: | The MOLT-4 cell line was established from cells taken from a patient in relapse who had received multidrug chemotherapy; the cells do not produce immunoglobulin or Epstein-Barr virus (Minowada, 1972). There is a G -> A mutation at codon 248 of the p53 gene; P53 is not expressed (Rodrigues, 1990). |
| Culture Medium: | RPMI 1640 medium supplemented with 2 mM L-glutamine and 10% fetal bovine serum. |
| Subculturing: | Subculture by diluting an aliquot of the cell suspension in fresh medium inside a new cell culture flask. Start new cultures at 4 X 105 cells/ml. The cell density should not exceed 2 x 106 cells/ml. |
| Fluid Renewal: | Add fresh medium every 2 to 4 days (depending on cell density) |
| Freeze Medium: | CM-1 (CLS ∙ Cell Lines Service) |
| Sterility: | Tests for mycoplasma, bacteria and fungi were negative |
| Biosafety Level: | 1 |
| Karyotype: | Hypertetraploid; modal number: 96; two X and two Y chromosomes. |
| DNA Profile (STR): | Amelogenin: X / Y CSF1PO: 11/12 D13S317: 12/13 D16S539: 11/14 D5S818: 12 D7S820: 8/10/11 THO1: 6,8 TPOX: 8 vWA: 17/18 D3S1358: 15/16 D21S11: 28/29/30 D18S51: 12/13/17 Penta E: 14/15/16 Penta D: 8/12/13 D8S1179: 9/13/14 FGA: 22/24 CLS ∙ Cell Lines Service, 2010. |
| Antigen Expression: | CD1 (49%), CD2 (35%), CD3 A (26%) B (33%) C (34%), CD4 (55%), CD5 (72%), CD6 (22%), CD7 (77%) |
| Products: | high levels of terminal deoxynucleotidyl transferase (TdT) are produced |
References: Minowada J et al. Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes. J Natl Cancer Inst 49: 891-5, 1972. Sahai Srivastava BI et al. Terminal deoxynucleotidyl transferase activity in a cell line (molt-4) derived from the peripheral blood of a patient with acute lymphoblastic leukaemia. Biochem Biophys Res Commun 51: 529-35, 1973. Takada A et al. Immunological functions of human T-lymphoid cell line (MOLT). I. Release of immunosuppressive factors from the mixture of MOLT-4 cells and sheep red blood cells. J Exp Med 140: 538-48, 1974. Ohsugi Y et al. Tumorigenicity of human malignant lymphoblasts: comparative study with unmanipulated nude mice, antilymphocyte serum-treated nude mice, and X- irradiated nude mice. J Natl Cancer Inst 65: 715-8, 1980. Greenberg et al. Immunophenotypic and cytogenetic analysis of Molt-3 and Molt-4: Human T-Lymphoid cell lines with rearrangement of chromosome 7. Blood 72(5): 1755-1760, 1988. Rodrigues NR et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 87: 7555-9, 1990. Sandstrom PA et al. Autocrine production of extracellular catalase prevents apoptosis of the human CEM T-cell line in serum-free medium. Proc Natl Acad Sci USA 90: 4708-12, 1993. Wunschmann S et al. In vitro interaction between Hepatitis C virus (HVC) envelope glycoprotein E2 and serum lipoproteins (LPs) results in enhanced cellular binding of both HCV E2 and LPs. J Infect Dis 194: 1058-67, 2006. Shin HY et al. The effect of Panax ginseng on forced immobility time & immune function in mice. Indian J Med Res 124: 199-206, 2006. | |
